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RESEARCH ARTICLEEstablishment of 2D Cell Cultures Derived From 3D MCF-7
Spheroids Displaying a Doxorubicin Resistant ProfileAna S. Nunes, Elisabete C. Costa, Andreia S. Barros, Duarte de Melo-Diogo,
and Ilídio J. Correia*In vitro 3D cancer spheroids generally exhibit a drug resistance profile similar
to that found in solid tumors. Due to this property, these models are an
appealing for anticancer compounds screening. Nevertheless, the techniques
and methods aimed for drug discovery are mostly standardized for cells
cultured in 2D. The development of 2D cell culture models displaying a drug
resistant profile is required to mimic the in vivo tumors, while the
equipment, techniques, and methodologies established for conventional 2D
cell cultures can continue to be employed in compound screening. In this
work, the response of 3D-derived MCF-7 cells subsequently cultured in 2D in
medium supplemented with glutathione (GSH) (antioxidant agent found in
high levels in breast cancer tissues and a promoter of cancer cells resistance)
to Doxorubicin (DOX) is evaluated. These cells demonstrated a resistance
toward DOX closer to that displayed by 3D spheroids, which is higher than
that exhibited by standard 2D cell cultures. In fact, the 50% inhibitory
concentration (IC50) of DOX in 3D-derived MCF-7 cell cultures supplemented
with GSH is about eight-times higher than that obtained for conventional 2D
cell cultures (cultured without GSH), and is only about two-times lower than
that attained for 3D MCF-7 spheroids (cultured without GSH). Further
investigation revealed that this improved resistance of 3D-derived MCF-7
cells may result from their increased P-glycoprotein (P-gp) activity and
reduced production of intracellular reactive oxygen species (ROS).1. Introduction
Cancer is a leading cause of death in both developed and
undeveloped countries.[1,2] Among the treatments used in the
clinic to treat this disease, chemotherapy is the most commonly
used.[3] However, tumor cells can acquire resistance toA. S. Nunes, E. C. Costa, A. S. Barros, D. de Melo-Diogo,
I. J. Correia
CICS-UBI – Health Sciences Research Centre
Universidade da Beira Interior
Avenida Infante D. Henrique, 6200-506 Covilh~a, Portugal
E-mail: icorreia@fcsaude.ubi.pt
I. J. Correia
CIEPQF – Departamento de Engenharia Química
Universidade de Coimbra
Rua Sílvio Lima, Polo II, 3030-790 Coimbra, Portugal
The ORCID identification number(s) for the author(s) of this article
can be found under https://doi.org/10.1002/biot.201800268.
DOI: 10.1002/biot.201800268
Biotechnol. J. 2019, 14, 1800268 © 21800268 (1 of 9)anticancer drugs (mostly due to the up-
regulation of multidrug resistance proteins
like drug efflux transporters [e.g., P-gp]),
which highlights the importance of devel-
oping more effective therapeutics.[2,4,5]
The validation of new anticancer agents
comprises several steps, includinganexhaus-
tive candidate selection during a preclinical
stage.During this stage, different in vitro (cell
cultures) and in in vivo (animals) assays are
performed to determine the pharmacological
propertiesof thedrug formulations, aswell as
their therapeutic action.[2,6] For this purpose,
the performance of a number of drugs has
beenanalyzedusing2Dinvitromodelsdue to
their simplicity, reproducibility, and low-
cost.[7–11] Still, these 2D in vitro models can
only beused to investigate the direct effects of
the drugs in the cells and do not take into
consideration the role of the physiological 3D
environment of the cells in drugs resistance.
Therefore, the exclusive use of 2D in vitro
models can lead to poor predictive results
concerning drug’s effectiveness.[12,13]Having
this in mind, 3D in vitro models, such as
tumor spheroids (small cellular aggregates
with a spherical-like shape), emerged in the
early 70s to serve as an intermediate model
betweenstandard2Dcell cultures andanimal
in vivo models.[11,14,15] Unlike the 2D in vitro
models, spheroids present a microenviron-mentandcellularorganizationthatgrant themahigherresistanceto
anticancer drugs.[16–22] Despite of the potential of spheroids for
compounds screening and the emergence of technologies for high-
throughput drug screening (HTS) in spheroids, these in vitro
models still present some challenges and limitations associated
(reviewed in refs. [23–27]). For instance, there is an urgent need to
optimize some of the spheroids production techniques in order to
attain these microtissues under highly reproducible conditions.
This is particularly important since spheroids with different
attributes (sizes and/or shapes) may be a source of results’
variability.[28–31] Another concern about the use of spheroids is
related to the lack of compatibility of the majority of the equipment
used for the analysis of 2D cell cultures with these 3D models and
also to the higher costs associated with the technologies developed
for the analysis of 3D cell cultures.[14,27,32] In particular, some
fluorescence microscopes (e.g., confocal analyzing modalities) are
not optimal for the imaging of large (>100μm in diameter) and018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.comdensespheroidsdue to the lightscattering, lightabsorptionandpoor
light penetration associated to prolonged imaging acquisition
times.[24,25,27]
Ontheotherhand, researchersaredevelopingdrugresistant2D
cell cultures.[7,33–40] These models show a drug resistance profile
more alike to that found in in vivo tumors and can be analyzed
throughstandardizedassaysandequipmentused for conventional
2D cell cultures. Recently, Koshkin et al. demonstrated that 3D-
derived MCF-7 cells (cells obtained from 3D spheroids disaggre-
gation) are able to preserve their 3D-phenotype when cultured in
2D.[7] Additionally, this phenotype was maintained for longer
periods (up to 96h) by culturing the 3D-derived cells in medium
supplemented with 5mM of glutathione (GSH; reducing and
antioxidantagent foundinhigh levels invariouscancer [e.g., breast
cancer] and an influencer of cancer cells resistance).[7,41–49]
However, so far, the applicability of the 3D-derived cells for
evaluating a drug response has not been investigated. Further-
more, the effect of drugs in 3D-derived cells in 2Dhas not yet been
compared to that occurring in conventional 2D models and 3D
spheroids.Therefore, thiswork intended to investigate the effect of
Doxorubicin (DOX; an anthracycline widely used in treatment of
several cancers, whose therapeutic effect is broadly reduced by the
cells resistance[50,51]) in 3D-derived MCF-7 cells (cultured in
presence and absence of GSH) and compare it to that observed in
MCF-7 cellscultured in2Dandas3Dspheroids.Then, thepossible
mechanismsthatprompted theincreasedresistance toDOXof3D-
derived cells were investigated, namely the P-gp activity and ROS
intracellular levels.2. Experimental Section
2.1. Materials
Estrogen-dependent human breast adenocarcinoma (MCF-7)
cells were acquired from ATCC (Middlesex, UK). Cell culture
plates and T-flasks were obtained from Thermo Fisher
Scientific (Porto, Portugal). 2’,7’-dichlorofluorescein diacetate
(H2DCFDA), Dulbecco’s Modified Eagle’s medium F-12
(DMEM-F12), ethylenediaminetetraacetic acid (EDTA), genta-
micin, L-glutathione (GSH), paraformaldehyde (PFA), phos-
phate-buffered saline solution (PBS), resazurin, rhodamine 123
(Rho 123), streptomycin, and trypsin were bought from Sigma–
Aldrich (Sintra, Portugal). Agarose was obtained from Grisp
(Porto, Portugal). Fetal bovine serum (FBS) was purchased
from Biochrom AG (Berlin, Germany). DOXwas obtained from
Carbosynth (Berkshire, UK). Cell imaging plates were acquired
from Ibidi GmbH (Ibidi). The store solution of DOX was
prepared in Methanol gotten from VWR International
(Portugal).2.2. Methods
2.2.1. Cells Maintenance and 3D MCF-7 Spheroids Formation
MCF-7 cells were cultured in DMEM-F12 supplemented with
FBS (10% [v/v]) and streptomycin and gentamycin (1% [v/v]) in
75 cm2 T-flasks. Cells were incubated in a humidifiedBiotechnol. J. 2019, 14, 1800268 1800268 (atmosphere at 37 C and 5% CO2.
[52] For spheroids formation,
agarose structures with spherical microwells were obtained by
using a micro-mold (3D Petri Dish, Microtissues Inc., Provi-
dence RI, USA) and then used to promote cells self-assembly, as
previously described by our group.[53] These agarose structures
were placed in cell culture plates (12-wells) and sterilized by UV
radiation during 60min. Afterwards, cells were seeded in the
agarose structures (1 106 cells/agarose structure). After some
period of time, the MCF-7 cells aggregate spontaneously,
allowing the obtention of 81 spheroids per agarose structure.
These spheroids were maintained in DMEM-F12 (FBS 10% [v/v]
and streptomycin and gentamycin 1% [v/v]) inside an incubator
with a humidified atmosphere (37 C, 5% CO2). The culture
medium of the spheroids was exchanged every 2 days. The
spheroids used in this study were allowed to grow for 10 days and
they displayed a mean diameter of 694.07 62.18 μm (analysis
performed by using ImageJ software [National Institutes of
Health], as previously described in our group[54,55]).2.2.2. Screening of DOX Effect on MCF-7 Cells Cultured in 2D
MCF-7 cells (12 400 cells/well) were seeded in 96-well culture
plates and then incubated for 24 h with cell culture medium with
or without GSH (5mM) supplementation.[7] Afterwards, the
medium was removed and cells were incubated with fresh cell
culture medium containing different concentrations of DOX
(0.1–200 μM). After 24 h, the culture medium was replaced by a
fresh one containing resazurin (10% [v/v]) for 4 h (37 C, 5%
CO2). Then, MCF-7 cells viability was assessed by analyzing the
fluorescence of resorufin (λex/λem¼ 560/590 nm) in a Spectra-
max Gemini EM spectroflorometer (Molecular Devices LLC, CA,
USA). Cells solely incubated with culture medium were used as
the negative control (K).
Subsequently, the drugs’ dose-response curves were traced in
order to determine the DOX 20, 50, and 80% inhibitory
concentrations (IC20, IC50, and IC80, respectively) using Origin-
Lab software (trial version, OriginPro, OriginLab Corporation,
MA, USA).[56,57]2.2.3. Screening of DOX Effect in MCF-7 Cells Cultured in
2.5D
3D MCF-7 spheroids were disaggregated by using 0.25% trypsin
(1:250) andEDTA0.1% (w/v). Afterwards, the 3D-derived cells were
seeded in 96-well culture plates at a density of 12 400 cells/well and
incubated for 24hwith fresh culturemediumwith or without GSH
(5mM) supplementation. Subsequently, cells were incubated with
culture medium containing DOX for 24h (1–200μM). Cells’
viability and theDOXinhibitory concentrationswere determined as
described in Section 2.2.2.2.2.4. Screening of DOX Effect on 3D MCF-7 Spheroids
3D MCF-7 spheroids were incubated for 24 h with fresh culture
medium containing DOX (25–200 μM). For each condition, a
total of 45 spheroids were used (total of five wells, each well with© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2 of 9)
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inhibitory concentrations were determined as described above in
Section 2.2.2.
The effect of DOX on 3DMCF-7 spheroids was also monitored
by acquiring optical microscopy images (Olympus CX41 inverted
optical microscope equipped with an Olympus SP-500 UZ digital
camera) and by measuring the spheroids diameter (this analysis
was performed by using ImageJ software (National Institutes of
Health), as previously described in our group (see for further
details Figure S1, Supporting Information).[54,55]2.2.5. Analysis of P-gp Activity Through Rho 123 Efflux Assay
The Rho 123 efflux assay was performed according to a protocol
previously reported in the literature with slight modifications.[58]
In brief, MCF-7 cells (obtained from 2D cell cultures or 3D-
derived) were cultured in 96-well culture plates at a density of
12 400 cells per well and incubated for 24 h with fresh medium
(with or without GSH 5mM). Then, the medium was replaced
with fresh medium containing Rho 123 (8mM). After MCF-7
cells’ incubation with the probe during 1 h, the medium
containing the probe was removed and fresh medium was added
to the wells. Then, the fluorescence of the medium in the wells
(that contains the Rho 123 expelled from the cells through the P-
gp) was measured at 2, 8, and 24 h (λex/λem¼ 507/525 nm) on a
Spectramax Gemini EM spectrofluorometer (Molecular Devices
LLC). For comparative purposes, the obtained fluorescence
intensity values were normalized with the fluorescence intensity
of the initial Rho 123 solution administrated to the cells.2.2.6. Rho 123 and DOX Accumulation in MCF-7 Cells
The analysis of the Rho 123 and DOX accumulation in the cells of
the different in vitromodels (2Dcell cultures and3D-derived cells)
was performed by adapting protocols previously described
elsewhere.[58–61] In brief, MCF-7 cells (obtained from 2D cell
cultures or 3D-derived)were cultured inμ-slide eight-well imaging
plates (IbidiGmbH,Munich,Germany)at adensityof12 400cells/
well in culture medium with or without GSH supplementation
(5mM). After 24h, the medium was replaced with freshmedium
containingRho123 (8mM)orDOX(9mM)for1 h.Then, cellswere
incubated with fresh medium during 8 and/or 24h. After this
period, the medium in the wells was removed, cells were
chemically fixed (using PFA 4% during 15min) and washed with
PBS. Afterwards, to determine the accumulation of Rho 123 and
DOX inside the MCF-7 cells, imaging experiments were
performed by using a Zeiss LSM 710 confocal microscope (Carl
Zeiss AG, Oberkochen, Germany) and processed in Carl Zeiss
software ZEN 2 software (the CLSM images were equally digitally
enhanced). Rho 123 and DOX were visualized by using λex/
λem¼ 514/519–650 and λex/λem¼ 488/535–674nm, respectively.2.2.7. Analysis of the ROS Levels in MCF-7 Cells Through
H2DCFDA Assay
Intracellular levels of ROS inMCF-7 cells were analyzed by using
H2DCFDA (a non-fluorescent compound that is converted to theBiotechnol. J. 2019, 14, 1800268 1800268 (highly fluorescent 2’,7’-dichlorofluorescein (DCF) in the pres-
ence of ROS), as previously described in literature.[62] In brief,
MCF-7 cells (obtained from 2D cell cultures or 3D-derived) at a
density of 12 400 cells/well were cultured during 24 h in μ-slide
eight-well imaging plates (Ibidi GmbH) in cell culture medium
with or without GSH supplementation (5mM). Then, cells were
incubated during 30min with hydrogen peroxide (H2O2; 0.3%
[v/v]). Afterwards, cells were washed with PBS and then
incubated with 10mM of a H2DCFDA in PBS for 1 h. Lastly,
the ROS levels in the cells were indirectly observed by imaging
the DCF fluorescence using a Zeiss LSM 710 confocal
microscope (Carl Zeiss AG) and using a λex of 488 nm and a
λem of 493–599 nm. The acquired images were processed in Carl
Zeiss software ZEN 2 software and all the images were equally
digitally enhanced. The DCF fluorescence intensity was
determined by using ImageJ software (National Institutes of
Health), as previously described elsewhere.[62–64] In brief, the
integrated density and the area of the CLSM image were
measured for each CLSM image, as well as the mean
fluorescence of the background (region without fluorescence).
Then, the Corrected Total Cell Fluorescence (CTCF) was
calculated according to Equation (1):
CTCF ¼ ⁢integrated density areað Þ
mean f luorescence of background ð1Þ2.2.8. Statistical Analysis
Data were expressed as mean values standard deviation (S.D.).
The statistical analysis was performed by using one-way ANOVA
test. A P-value lower than 0.05 (P< 0.05) was considered
statistically significant. Data analysis was performed in Graph-
Pad Prism v.6.0 software (Trial version, GraphPad Software, CA,
USA).3. Results and Discussion
2D cell cultures exhibiting resistance to anticancer drugs are
promising models for compounds screening. Furthermore,
resistant 2D cell cultures can be analyzed by conventional and
standardized techniques/methodologies. The most commonly
used breast cancer resistant 2D cell culture model is the MCF-7/
ADR cells.[36,65,66] These cells are generally obtained by
maintaining MCF-7 cells in culture medium supplemented
with DOX for long periods of time.[33,34,36] For instance, Desrini
et al. obtained Doxorubicin resistant MCF-7 cell by exposing
parental MCF-7 cells to DOX twice a week for a period of
25 days.[36] Optionally, resistant MCF-7 cells can also be obtained
by exposing them to hypoxic cycles (e.g., <1% oxygen),[37,38]
since the hypoxia triggers the activation of a plethora of
molecular pathways involved in cancer cells’ resistance
(reviewed in refs. [37,39,40]). As an example, Hamdan and
Zihlif obtained MCF-7 cells resistant to DOX by subjecting the
cells to hypoxia for 8 h, repeating this process three times a
week.[37] However, these procedures can be expensive, time-
consuming and may require specific equipment (e.g., anaerobic© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim3 of 9)
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under certain conditions.[67–70] Therefore, there is an urgent
need to develop new resistant 2D cell culture models that can be
attained using inexpensive and simple processes, and that at the
same time, display a drug-resistant profile similar to that found
in tumor spheroids and in in vivo solid tumors.
In this study, a resistant 2D cell culture model of breast cancer
(termed as 2.5D[þGSH] MCF-7 cell culture) was obtained by a
simplemethod that takes less than 2 weeks (Figure 1). Thismodel
was produced by culturing in 2D theMCF-7 cells obtained from10
days-old 3D spheroids. The reasoning for this approach lays in the
fact that several reports have demonstrated that 3D-derived cells
presentdifferentproperties fromtheirequivalentsculturedonly in
2D.[7,71] Furthermore, 3D-derived cells can also maintain their 3D
phenotype upon spheroids disassociation (e.g., proliferation rate,
drug expelling capacity).[7,71] Herein, the 3D-derived MCF-7 cells
were cultured in medium supplemented with GSH (5mM) since
GSH: 1) is present in high concentrations in breast cancer tissues
(in comparison to disease-free breast tissue);[49,72] 2) influences
cells’ proliferation and death;[73] 3) influences cells’ resistance to
therapeutics and radiation;[43–48,73] and 4) can maintain for long
periods of time the3Dphenotype of 3D-derived cells (up to 96h).[7]
Furthermore, the effect of DOX on the viability of 2.5D(þGSH)
MCF-7 cells was determined and compared with that occurring in
conventional 2D cell cultures (2D[GSH] MCF-7 cells) and 3D
MCF-7 spheroids. The mechanisms that may be involved in
2.5D(þGSH) MCF-7 cells’ resistance to DOX were also
investigated.3.1. 2D, 2.5D, and 3D Breast Cancer Cell Cultures
Response to Doxorubicin
The effect of DOX in the viability of traditional 2D cell cultures
(2D[GSH] MCF-7 cells) and 2.5D(þGSH) MCF-7 cell cultures
was first investigated (Figure 2A,B; Table S1–S3, Supporting
Information). Then, DOX-response curves were obtained inFigure 1. Schematic illustration of the MCF-7 cell cultures used in this wor
cultures that grow in absence of GSH); 2D(þGSH) cultures (traditional 2D
derived cell cultures that grow in absence of GSH); 2.5D(þGSH) cultures (3
Biotechnol. J. 2019, 14, 1800268 1800268 (order determine the drug concentrations required to reduce
cells’ viability by 20, 50, and 80% (IC20, IC50, IC80). It was
verified that 2.5D(þGSH) MCF-7 cells were less affected by
DOX when compared to 2D MCF-7 cells (IC20¼ 37.49mM;
IC50¼ 68.68mM; IC80¼ 125.83mM vs. IC20¼ 3.14mM; IC50
¼ 9.04mM; IC80¼ 26.03mM). In fact, the inhibitory concen-
trations revealed that the IC50 of DOX in 2.5D(þGSH) MCF-7
cells was eightfold higher than the IC50 value obtained for the
traditional 2D cell cultures (2D[GSH] MCF-7 cells). The
higher resistance of 2.5D(þGSH) MCF-7 cells to DOX
(26.03 μM) was maintained up to 48 h of cultures’ establish-
ment (Figure S2, Supporting Information). The resistance to
DOX displayed by 2.5D(þGSH) MCF-7 cells is dependent on
the GSH supplementation and on the 3D-derivation of these
cells, while the 2D cell cultures sensibility to DOX was not
significantly influenced by the GSH (Figure 2E). On the other
hand, 3D-derived cells without GSH supplementation (2.5D-
[GSH] cells) could display (at low doses of DOX [3.14 μM])
some resistance to the effect of DOX. In stark contrast,
2.5D(þGSH) cells were less affected by DOX (at various
concentrations of DOX [9.04 and 26.03 μM]), thereby confirm-
ing the improved DOX resistance profile displayed by this
model.
To compare the level of resistance of the 2.5D(þGSH) to that
displayed by 3D cell cultures, the effect of the DOX in 3DMCF-7
spheroids and its drug-response curves were also determined
(Figure 2C). As expected, DOX induced a decrease on the
spheroids’ size (Figure S3, Supporting Information).[74,75] The
IC20, IC50, and IC80 of DOX in the 3D spheroids were
determined to be 73.96, 110.09, and 163.97mM, respectively
(Figure 2C). Spheroids are more resistant to the effect of DOX
when compared to 2.5D(þGSH) cells. This result was expected
since spheroids’ resistance to drugs is influenced by several
factors (reviewed in detail in refs. [6,76,77]). As example,
spheroids often demonstrate increased expression of ECM
proteins (e.g., collagen, fibronectin) that can influence cancer
cells’ resistance to different therapeutics, such as DOX.[78–80]k. During the study, it was used 2D(GSH) cultures (traditional 2D cell
cell cultures that grow in presence of GSH); 2.5D(GSH) cultures (3D-
D-derived cell cultures that grow in presence of GSH); and 3D spheroids.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim4 of 9)
Figure 2. Evaluation of the DOX effect on the cellular viability of 2D, 2.5D, and 3D MCF-7 cell cultures. Dose-response curves of 2D(GSH) (A),
2.5D(þGSH) (B), and 3D (C) MCF-7 cell cultures to DOX. Comparison of 20, 50, and 80% inhibitory concentrations of DOX (IC20, IC50, and IC80) in
2D(GSH), 2.5D(þGSH), and 3D MCF-7 cell cultures (D). Cell viability of the different models after the administrations of several concentrations of
DOX (3.14, 9.04, and 26.04 μM) during 24 h (values were normalized toward the cell viability of 2D[GSH] cells which was considered the traditional cell
culture model) (E); data are presented as mean S.D. (n¼ 5); P< 0.05.
www.advancedsciencenews.com www.biotechnology-journal.comHowever, 2.5D(þGSH) cells’ DOX resistance profile is closer to
that displayed by 3D spheroids when compared to conventional
2D models (Figure 2D). Together, these results confirm that the
2D cultures of MCF-7 cells derived from 3D spheroids cultured
in the presence of GSH are an alternative in vitro model of DOX
resistant breast cancer cells.3.2. Characterization of 2.5D(þGSH) Breast Cancer Cell
Culture Resistance Mechanisms Toward DOX
High expression of efflux pumps is often associated with the
increased resistance displayed by cancer cells to different
drugs.[7,81] One of the mechanisms potentially contributing to
the resistance exhibited by cancer cells to DOX, involves the up-
regulation of P-gp expression (proteins that mediates DOX
transport from cells).[7,81] Various studies have demonstrated that
GSH can affect the expression of this multidrug resistance (MDR)
transporter,[43,47,48] and it has been found that increased
intracellular GSH or GSH related enzymes have been associated
withMDR.[47,82]Hongetal. observed that thetreatmentofcellswith
Buthionine Sulfoximine (BSO; an inhibitor of γ-Glutamylcysteine
synthetase [γ-GCS], an enzyme that is responsible for GSH
synthesis), decreases the levels of GSH in the cells and induces the
down-regulation of the P-gp expression.[43] Therefore, theBiotechnol. J. 2019, 14, 1800268 1800268 (increased DOX resistance displayed by 2.5D(þGSH) cells may
be mediated by an up-regulation of the P-gp function due to the
increase levels of GSH in these cells.
To confirm this hypothesis, the efflux of Rho 123, as well as its
accumulation inside the cells cultured in 2D and 2.5D, in the
presenceandabsenceofGSH,wasevaluated (Figure 3). Rho123 is
afluorescent probe that interactswith different transport proteins,
but in a greater extent with the P-gp.[58–61,83,84] The data obtained
throughfluorescence spectroscopy demonstrates that the efflux of
Rho123occursover time inall the typesofMCF-7cultures (2Dand
2.5D cultures maintained in presence and absence of GSH)
(Figure 3B). After 24h of cells being incubated with Rho 123, 2.5
(þGSH) MCF-7 cells demonstrated 47.37 8.87% of Rho 123
efflux, while the traditional 2D cell cultures (2D[GSH] MCF-7
cells) showed only 33.20 6.79% (Figure 3B). Furthermore, 2.5D
MCF-7 cells cultured in the presence of GSH displayed a higher
Rho 123 efflux when compared to their equivalents without GSH
supplementation (Figure 3B).
To corroborate these observations, the accumulation ofRho 123
and DOX in the cellular compartments of the MCF-7 cells was
assessed through CLSM images (Figure 3C,D). As expected, the
lowest accumulation of the Rho 123 at 8 and 24h occurred in the
2.5D(þGSH) MCF-7 cells (Figure 3C4,C8). The same profile was
also observed for DOX, that is, the 2.5D(þGSH) group displayed
the lowest accumulation of DOX (Figure 3D4). These results© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim5 of 9)
Figure 3. Evaluation of the P-gp function in MCF-7 cells. Schematic representation of the Rho 123 efflux mechanism in MCF-7 cells (A). Normalized Rho
123 efflux in 2D(GSH), 2D(þGSH), 2.5D(GSH), and 2.5D(þGSH) MCF-7 cells (Rho 123 efflux was quantified by fluorescence spectroscopy, λex/
λem¼ 507/525 nm; values were normalized with the fluorescence intensity of the initial Rho 123 solution administrated to the cells); data are presented
as mean S.D. (n¼ 5); P< 0.05 (B). CLSM images of the accumulation of Rho 123 (C) and DOX (D) in 2D(GSH), 2D(þGSH), 2.5D(GSH), and
2.5D(þGSH) MCF-7 cells; yellow channel: Rho 123 (λex/λem¼ 514/519–650 nm); red channel: DOX (λex/λem¼ 488/535–674 nm); scale bars correspond
to 50mm.
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Figure 4. Evaluation of the ROS levels in MCF-7 cells. CLSM images of the ROS generation by 2D(GSH), 2D(þGSH), 2.5D(GSH), and 2.5D(þGSH)
MCF-7 cells through the H2DCF-DA assay. Cells were grown during 24 h, then treated with hydrogen peroxide (H2O2) during 30min before their
incubation with H2DCFDA during 1 h. The values indicate the Corrected Total Cell Fluorescence (CTCF) measured in each image. Blue channel:
H2DCFDA oxidized (DCF) by ROS (λex/λem¼ 488/493–599 nm); scale bars correspond to 50mm.
www.advancedsciencenews.com www.biotechnology-journal.comdisclose that one of the mechanisms that may be involved in
2.5D(þGSH) cells improved resistance to DOX is probably due to
an increase of theP-gpactivity,which is influencedby thepresence
of GSH as previously demonstrated in the literature.[7,73,82,85–88]
Besides, this in vitro model may also be interesting to evaluate
other therapeutics that are usually explelled by the P-gp, such as
Colchicine, Paclitaxe, and Vinblastinel.[89]
Moreover, the therapeutic efficacy of DOX may be limited by
ROS scavengers, such as GSH.[90–92] In fact, DOX-induced ROS
production is a major mechanism of action of this drug
(excessive amount of ROS causes oxidative damage to lipids,
proteins and DNA,[88] and leads to the activation of signaling
pathways involved in cancer cells apoptosis).[73,88,93,94] As an
antioxidant, GSH stabilizes the redox state of the cells by ROS
scavenging, as previously discussed.[88,95–99] A study performed
by Armstrong et al. demonstrated that the treatment of cells with
BSO (inhibitor of GSH synthesis) resulted in an early decline in
cellular GSH, followed by an increase of ROS levels, which
further led to the induction of various apoptotic signals.[45] In a
more recent study, it was demonstrated that the treatment of
T47D breast cancer cells with BSO/DOX drug combination
reduced more the cancer cells’ survival than the single
administration of DOX, since the BSO (inhibitor of GSH
synthesis) acts synergistically with DOX to produce oxidative
stress (e.g., ROS production).[100] Therefore, H2DCFDA cellular
ROS detection assay was performed to elucidate if GSH
influenced the 2.5D(þGSH) MCF-7 cells resistance to DOX
by decreasing the ROS levels in these cells (Figure 4). In this type
of assay, greater fluorescence signals in the cells are directly
correlated with a higher presence of ROS. According to the
CLSManalysis, the 2.5D(þGSH)MCF-7 cells displayed a weaker
fluorescence intensity (CTCF¼ 42880.34), when compared to
2D(GSH), 2D(þGSH), and 2.5D(GSH) MCF-7 cell cultures
(CTCF¼ 80759.52, 80300.16, and 65906.00, respectively) (Fig-
ure 4). This indicates that ROS levels are lower in the
2.5D(þGSH) model, probably due to its higher ROS scavenging
capacity. Therefore, decreased ROS levels may be another
mechanism that is responsible for the resistance of 2.5D(þGSH)
cells to DOX. Additionally, this model may also be useful for the
analysis of other ROS-dependent therapeutics, such as Bleomy-
cin, Cisplatin and Diclofenac.[101,102]Biotechnol. J. 2019, 14, 1800268 1800268 (4. Conclusion
Resistant 2D cell cultures can closely mimic the drug resistance
profile presented by the in vivo tumors. In this study, it was
demonstrated that a DOX-resistant 2D cell culture model can be
obtained in a short-period by collecting the cells obtained from
dissociated 10 days-old spheroids and by culturing these cells in
medium supplemented with GSH (2.5D[þGSH] MCF-7 cell
cultures). This in vitro model displays a drug resistance profile to
DOX closer to that displayed by 3D spheroids, and higher than
that obtained in 2D cell cultures. Results also showed that the
resistance of 2.5D(þGSH) MCF-7 cells may be associated with
its increased P-gp function and ROS scavenging levels. Overall,
this study demonstrates that resistant 2D MCF-7 cell cultures
can be a promising tool for drug screening aimed for breast
cancer treatment, since this model is compatible with the
methodologies and techniques that are already used for the
analysis of conventional 2D in vitro assays.Abbreviations
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